656 related articles for article (PubMed ID: 21221766)
81. Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results.
Loibl S; Turner NC; Ro J; Cristofanilli M; Iwata H; Im SA; Masuda N; Loi S; André F; Harbeck N; Verma S; Folkerd E; Puyana Theall K; Hoffman J; Zhang K; Bartlett CH; Dowsett M
Oncologist; 2017 Sep; 22(9):1028-1038. PubMed ID: 28652278
[TBL] [Abstract][Full Text] [Related]
82. Neoadjuvant chemotherapy-induced changes in immunohistochemical expression of estrogen receptor, progesterone receptor, HER2, and Ki-67 in patients with breast cancer.
Avci N; Deligonul A; Tolunay S; Cubukcu E; Fatih Olmez O; Ulas A; Hartavi M; Kurt E; Evrensel T
J BUON; 2015; 20(1):45-9. PubMed ID: 25778295
[TBL] [Abstract][Full Text] [Related]
83. Pathological lymph node involvement at surgery is a significant predictive factor of recurrence in locally advanced breast cancer treated with concomitant epirubicin-docetaxel neoadjuvant chemotherapy: a cohort study.
Kai K; Arima N; Miyayama H; Yamamoto Y; Iwase H; Nishimura R
Breast Cancer; 2009; 16(1):42-8. PubMed ID: 18504642
[TBL] [Abstract][Full Text] [Related]
84. Randomized phase 2 neoadjuvant trial evaluating anastrozole and fulvestrant efficacy for postmenopausal, estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients: Results of the UNICANCER CARMINA 02 French trial (UCBG 0609).
Lerebours F; Rivera S; Mouret-Reynier MA; Alran S; Venat-Bouvet L; Kerbrat P; Salmon R; Becette V; Bourgier C; Cherel P; Boussion V; Balleyguier C; Thibault F; Lavau-Denes S; Nabholz JM; Sigal B; Trassard M; Mathieu MC; Martin AL; Lemonnier J; Mouret-Fourme E
Cancer; 2016 Oct; 122(19):3032-40. PubMed ID: 27315583
[TBL] [Abstract][Full Text] [Related]
85. Tumor characteristics and therapy of elderly patients with breast cancer.
Grumpelt AM; Ignatov A; Tchaikovski SN; Burger E; Costa SD; Eggemann H
J Cancer Res Clin Oncol; 2016 May; 142(5):1109-16. PubMed ID: 26809246
[TBL] [Abstract][Full Text] [Related]
86. Combination of trastuzumab and letrozole after resistance to sequential trastuzumab and aromatase inhibitor monotherapies in patients with estrogen receptor-positive, HER-2-positive advanced breast cancer: a proof-of-concept trial (SAKK 23/03).
Koeberle D; Ruhstaller T; Jost L; Pagani O; Zaman K; von Moos R; Oehlschlegel C; Crowe S; Pilop C; Thuerlimann B;
Endocr Relat Cancer; 2011 Apr; 18(2):257-64. PubMed ID: 21317203
[TBL] [Abstract][Full Text] [Related]
87. Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer.
Jones RL; Salter J; A'Hern R; Nerurkar A; Parton M; Reis-Filho JS; Smith IE; Dowsett M
Breast Cancer Res Treat; 2010 Jan; 119(2):315-23. PubMed ID: 19247830
[TBL] [Abstract][Full Text] [Related]
88. Antitumor activity of chemoendocrine therapy in premenopausal and postmenopausal models with human breast cancer xenografts.
Kataoka M; Yamaguchi Y; Moriya Y; Sawada N; Yasuno H; Kondoh K; Evans DB; Mori K; Hayashi S
Oncol Rep; 2012 Feb; 27(2):303-10. PubMed ID: 22076074
[TBL] [Abstract][Full Text] [Related]
89. High expression of post-treatment Ki-67 status is a risk factor for locoregional recurrence following breast-conserving surgery after neoadjuvant chemotherapy.
Yamazaki N; Wada N; Yamauchi C; Yoneyama K
Eur J Surg Oncol; 2015 May; 41(5):617-24. PubMed ID: 25771264
[TBL] [Abstract][Full Text] [Related]
90. Receptor discordances after neoadjuvant chemotherapy and their effects on survival.
Tural D; Karaca M; Zirtiloglu A; M Hacioglu B; Sendur MA; Ozet A
J BUON; 2019; 24(1):20-25. PubMed ID: 30941947
[TBL] [Abstract][Full Text] [Related]
91. Quantitative ER and PgR assessment as predictors of benefit from lapatinib in postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer.
Finn RS; Press MF; Dering J; O'Rourke L; Florance A; Ellis C; Martin AM; Johnston S
Clin Cancer Res; 2014 Feb; 20(3):736-43. PubMed ID: 24198242
[TBL] [Abstract][Full Text] [Related]
92. Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer.
Grassadonia A; Di Nicola M; Grossi S; Noccioli P; Tavoletta S; Politi R; Angelucci D; Marinelli C; Zilli M; Ausili Cefaro G; Tinari N; De Tursi M; Iezzi L; Cioffi P; Iacobelli S; Natoli C; Cianchetti E
Ann Surg Oncol; 2014 May; 21(5):1575-82. PubMed ID: 24522992
[TBL] [Abstract][Full Text] [Related]
93. Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer.
Penault-Llorca F; André F; Sagan C; Lacroix-Triki M; Denoux Y; Verriele V; Jacquemier J; Baranzelli MC; Bibeau F; Antoine M; Lagarde N; Martin AL; Asselain B; Roché H
J Clin Oncol; 2009 Jun; 27(17):2809-15. PubMed ID: 19380452
[TBL] [Abstract][Full Text] [Related]
94. Treatment patterns of elderly breast cancer patients at two Canadian cancer centres.
Angarita FA; Chesney T; Elser C; Mulligan AM; McCready DR; Escallon J
Eur J Surg Oncol; 2015 May; 41(5):625-34. PubMed ID: 25727372
[TBL] [Abstract][Full Text] [Related]
95. Clinicopathological features of early failure of neoadjuvant chemotherapy in locally advanced breast cancer.
Choi MK; Park YH; Kil WH; Lee JE; Nam SJ; Ahn JS; Im YH
Cancer Chemother Pharmacol; 2014 Sep; 74(3):521-9. PubMed ID: 25047725
[TBL] [Abstract][Full Text] [Related]
96. Evaluation of ER, PgR, HER-2, Ki-67, cyclin D1, and nm23-H1 as predictors of pathological complete response to neoadjuvant chemotherapy for locally advanced breast cancer.
Li XR; Liu M; Zhang YJ; Wang JD; Zheng YQ; Li J; Ma B; Song X
Med Oncol; 2011 Dec; 28 Suppl 1():S31-8. PubMed ID: 20844986
[TBL] [Abstract][Full Text] [Related]
97. Efficacy of goserelin plus anastrozole in premenopausal women with advanced or recurrent breast cancer refractory to an LH-RH analogue with tamoxifen: results of the JMTO BC08-01 phase II trial.
Nishimura R; Anan K; Yamamoto Y; Higaki K; Tanaka M; Shibuta K; Sagara Y; Ohno S; Tsuyuki S; Mase T; Teramukai S
Oncol Rep; 2013 May; 29(5):1707-13. PubMed ID: 23446822
[TBL] [Abstract][Full Text] [Related]
98. Placental weight and mortality in premenopausal breast cancer by tumor characteristics.
Hajiebrahimi MH; Bahmanyar S; Lambe M; Adolfsson J; Fornander T; Wärnberg F; Cnattingius S
Breast Cancer Res Treat; 2013 Jan; 137(1):297-305. PubMed ID: 23149466
[TBL] [Abstract][Full Text] [Related]
99. Surgery improves survival in elderly with breast cancer. A study of 465 patients in a single institution.
Cortadellas T; Córdoba O; Gascón A; Haladjian C; Bernabeu A; Alcalde A; Esgueva A; Rodriguez-Revuelto R; Espinosa-Bravo M; Díaz-Botero S; Xercavins J; Rubio IT; Gil-Moreno A
Eur J Surg Oncol; 2015 May; 41(5):635-40. PubMed ID: 25703077
[TBL] [Abstract][Full Text] [Related]
100. Evaluation of ER and Ki-67 proliferation index as prognostic factors for survival following neoadjuvant chemotherapy with doxorubicin/docetaxel for locally advanced breast cancer.
Lee J; Im YH; Lee SH; Cho EY; Choi YL; Ko YH; Kim JH; Nam SJ; Kim HJ; Ahn JS; Park YS; Lim HY; Han BK; Yang JH
Cancer Chemother Pharmacol; 2008 Apr; 61(4):569-77. PubMed ID: 17508214
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
